-
American Journal of Transplantation :... Jul 2011
Topics: Antibodies, Monoclonal; Antilymphocyte Serum; Basiliximab; Humans; Kidney Transplantation; Lymphocyte Depletion; Receptors, Interleukin-2; Recombinant Fusion Proteins
PubMed: 21564527
DOI: 10.1111/j.1600-6143.2011.03543.x -
American Journal of Transplantation :... Sep 2018
Topics: Antilymphocyte Serum; Child; Heart Transplantation; Humans; Incidence; Tissue Donors
PubMed: 29947127
DOI: 10.1111/ajt.14986 -
Bone Marrow Transplantation Jun 2020This collaborative initiative aimed to provide recommendations on the use of polyclonal antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the... (Review)
Review
This collaborative initiative aimed to provide recommendations on the use of polyclonal antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). A comprehensive review of articles released up to October, 2018 was performed as a source of scientific evidence. Fourteen clinically relevant key questions to the domains indication, administration, and post-transplant management were developed and recommendations were produced using the Delphi technique involving a Panel of 14 experts. ATG/ATLG was strongly recommended as part of myeloablative conditioning regimen prior to matched or mismatched unrelated bone marrow or peripheral blood allogeneic HSCT in malignant diseases to prevent severe acute and chronic GvHD. ATG/ATLG was also recommended prior to HLA-identical sibling peripheral HSCT with good but lesser bulk of evidence. In reduced intensity or nonmyeloablative conditioning regimens, ATG/ATLG was deemed appropriate to reduce the incidence of acute and chronic GvHD, but a higher risk of relapse should be taken into account. Recommendations regarding dose, application, and premedication were also provided as well as post-transplant infectious prophylaxis and vaccination. Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT.
Topics: Animals; Antilymphocyte Serum; Consensus; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Neoplasm Recurrence, Local; Rabbits; Transplantation Conditioning
PubMed: 31969678
DOI: 10.1038/s41409-020-0792-x -
Bristol Medico-chirurgical Journal... Jul 1970
Review
Topics: Antilymphocyte Serum; Biliary Tract Diseases; Blood Coagulation; Histocompatibility; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Postoperative Complications; Tissue Donors; Tissue Preservation; Transplantation Immunology; Transplantation, Homologous
PubMed: 4919557
DOI: No ID Found -
Nefrologia : Publicacion Oficial de La... 2016Steroid minimization after kidney transplantation has become more widely practiced as transplant clinicians seek the potential benefits such as reduced cardiovascular... (Review)
Review
Steroid minimization after kidney transplantation has become more widely practiced as transplant clinicians seek the potential benefits such as reduced cardiovascular risk factors, improved growth in pediatric patients, and improved compliance with the immunosuppression regimen. Steroid avoidance (i.e. no steroids after the first week) is generally favored compared to later withdrawal. Induction therapy is routine in this setting, frequently rabbit antithymocyte globulin (rATG, Thymoglobulin®) or off-license use of alemtuzumab. Direct comparisons of steroid minimization regimens versus standard steroid regimens are rare. However, the available data show that the risk of acute rejection is low when rATG or alemtuzumab induction is given to support steroid-avoidance regimens after kidney transplantation. Steroid avoidance may be inadvisable in patients at high immunological risk or at risk of recurrent glomerular disease. Steroid withdrawal after day 8 may be possible without additional risk of rejection in patients given rATG induction, but while encouraging, the data are too sparse for firm conclusions. In summary, steroid avoidance may be beneficial for patients after renal transplantation, with the potential to avoid or reduce steroid-related comorbidities. Whilst depleting induction therapy could be the treatment of choice, results of prospective randomized, controlled studies are eagerly awaited.
Topics: Alemtuzumab; Animals; Antilymphocyte Serum; Cardiovascular Diseases; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Depletion; Risk Factors; Steroids
PubMed: 27184648
DOI: 10.1016/j.nefro.2016.03.019 -
Seminars in Hematology Oct 2012It is now well accepted that a subgroup of patients with myelodysplastic syndromes (MDS) can recover from pancytopenia following immunosuppressive treatment (IST). For... (Review)
Review
It is now well accepted that a subgroup of patients with myelodysplastic syndromes (MDS) can recover from pancytopenia following immunosuppressive treatment (IST). For many years immunosuppression with antilymphocyte antibodies has been a standard treatment approach for patients with severe aplastic anemia (SAA). The initial concept of using immunosuppression to treat pancytopenic patients with MDS was based on the premise that MDS might share with SAA an autoimmune basis for the bone marrow failure common to both conditions. The idea was supported by reports of favorable outcomes in occasional cases of MDS treated with antithymocyte globulin (ATG). Today, various forms of IST have been successfully used to restore hematopoiesis in MDS in many centers worldwide. In this review we outline the rationale for use of IST in MDS, and describe studies which help to define the patients with MDS likely to respond to IST. We summarize 18 published clinical trials using IST for MDS and discuss how these studies have helped to define the MDS subgroups likely to respond to treatment, the nature and durability of the response, the impact of IST on long-term outcome, and the best treatment approach.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Cyclosporine; Humans; Immunologic Factors; Immunosuppressive Agents; Myelodysplastic Syndromes; Treatment Outcome
PubMed: 23079060
DOI: 10.1053/j.seminhematol.2012.07.004 -
Haematologica Apr 2014
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclosporine; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Pancytopenia
PubMed: 24688105
DOI: 10.3324/haematol.2014.105569 -
Journal of the American Society of... Nov 2016
Topics: Antilymphocyte Serum; CD4-Positive T-Lymphocytes; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation
PubMed: 27225038
DOI: 10.1681/ASN.2016040470 -
American Journal of Transplantation :... Mar 2019
Topics: Antilymphocyte Serum; Graft Rejection
PubMed: 30203616
DOI: 10.1111/ajt.15114 -
Clinical Journal of the American... Jun 2015
Topics: Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Calcineurin Inhibitors; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Living Donors; Male; Mycophenolic Acid; Steroids; Tacrolimus
PubMed: 25979977
DOI: 10.2215/CJN.03800415